NO20073286L - Stabile krystallmodifikasjoner av DOTAP-klorid - Google Patents

Stabile krystallmodifikasjoner av DOTAP-klorid

Info

Publication number
NO20073286L
NO20073286L NO20073286A NO20073286A NO20073286L NO 20073286 L NO20073286 L NO 20073286L NO 20073286 A NO20073286 A NO 20073286A NO 20073286 A NO20073286 A NO 20073286A NO 20073286 L NO20073286 L NO 20073286L
Authority
NO
Norway
Prior art keywords
stable crystal
dotap chloride
crystal modifications
modifications
chloride
Prior art date
Application number
NO20073286A
Other languages
English (en)
Other versions
NO338885B1 (no
Inventor
Michael Platscher
Alfred Hedinger
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20073286L publication Critical patent/NO20073286L/no
Publication of NO338885B1 publication Critical patent/NO338885B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører enantiomert rent DOTAP-klorid og stabile krystallmodifikasjoner av (2R,S)-, (2S)- og (2R)-DOTAP-klorid, en fremgangsmåte for fremstilling av disse modifikasjonene og anvendelsen derav som bestanddel for fremstillingen av medikamenter.
NO20073286A 2004-11-26 2007-06-25 Enantiomerisk rent (2R)-1,2-dioleoyloksy-3-trimetylammoniumpropanklorid ((2R) -DOTAP klorid), anvendelse derav som bestanddel ved fremstillingen av legemidler og farmasøytisk sammensetning derav. NO338885B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004057303A DE102004057303A1 (de) 2004-11-26 2004-11-26 Stabile Kristallmodifikationen von DOTAP Chlorid
PCT/EP2005/011874 WO2006056312A1 (de) 2004-11-26 2005-11-07 Stabile kristallmodifikationen von dotap chlorid

Publications (2)

Publication Number Publication Date
NO20073286L true NO20073286L (no) 2007-06-25
NO338885B1 NO338885B1 (no) 2016-10-31

Family

ID=35789283

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073286A NO338885B1 (no) 2004-11-26 2007-06-25 Enantiomerisk rent (2R)-1,2-dioleoyloksy-3-trimetylammoniumpropanklorid ((2R) -DOTAP klorid), anvendelse derav som bestanddel ved fremstillingen av legemidler og farmasøytisk sammensetning derav.

Country Status (21)

Country Link
US (2) US8853283B2 (no)
EP (1) EP1814843B1 (no)
JP (1) JP4880612B2 (no)
KR (1) KR101249370B1 (no)
CN (2) CN101065350A (no)
AU (1) AU2005309107B2 (no)
BR (2) BR122019018186B8 (no)
CA (1) CA2589218C (no)
DE (1) DE102004057303A1 (no)
ES (1) ES2545906T3 (no)
HK (1) HK1178143A1 (no)
HU (1) HUE027554T2 (no)
IL (1) IL183324A (no)
MX (1) MX2007006128A (no)
NO (1) NO338885B1 (no)
NZ (2) NZ582382A (no)
PL (1) PL1814843T3 (no)
PT (1) PT1814843E (no)
RU (1) RU2463291C2 (no)
WO (1) WO2006056312A1 (no)
ZA (1) ZA200705169B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US9789129B2 (en) 2008-04-17 2017-10-17 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2012159704A1 (en) * 2011-05-20 2012-11-29 Merck Patent Gmbh Stable crystal modifications of dotap chloride
BR112013029834A8 (pt) 2011-05-24 2022-10-18 Biontech Ag vacinas individualizadas para câncer
WO2013039989A1 (en) * 2011-09-12 2013-03-21 Pds Biotechnology Corporation Particluate vaccine formulations
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
US10155031B2 (en) 2012-11-28 2018-12-18 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
AU2016354590B2 (en) 2015-11-13 2023-11-23 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
EP0902682A2 (en) * 1996-05-08 1999-03-24 Nika Health Products Limited Cationic virosomes as transfer system for genetic material
WO1998010748A1 (en) * 1996-09-13 1998-03-19 The School Of Pharmacy Liposomes
US6458382B1 (en) * 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
ES2183720B1 (es) 2001-06-18 2004-01-16 Esteve Labor Dr Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras.
ITMI20032185A1 (it) 2003-11-12 2005-05-13 Chemi Spa Processo per la sintesi di lipidi cationici.

Also Published As

Publication number Publication date
US20140370081A1 (en) 2014-12-18
CN102796016B (zh) 2015-09-02
US9457087B2 (en) 2016-10-04
BRPI0518489B1 (pt) 2020-03-31
CN101065350A (zh) 2007-10-31
ZA200705169B (en) 2008-08-27
NZ556060A (en) 2010-03-26
JP4880612B2 (ja) 2012-02-22
DE102004057303A1 (de) 2006-06-01
RU2007123673A (ru) 2009-01-10
KR101249370B1 (ko) 2013-04-01
NO338885B1 (no) 2016-10-31
RU2463291C2 (ru) 2012-10-10
IL183324A (en) 2013-10-31
CA2589218C (en) 2013-12-17
BR122019018186B1 (pt) 2021-03-09
AU2005309107B2 (en) 2011-07-21
WO2006056312A1 (de) 2006-06-01
ES2545906T3 (es) 2015-09-16
NZ582382A (en) 2010-08-27
AU2005309107A1 (en) 2006-06-01
EP1814843B1 (de) 2015-06-24
PL1814843T3 (pl) 2015-11-30
BRPI0518489B8 (pt) 2021-05-25
KR20070084501A (ko) 2007-08-24
PT1814843E (pt) 2015-10-13
US8853283B2 (en) 2014-10-07
CA2589218A1 (en) 2006-06-01
CN102796016A (zh) 2012-11-28
HK1178143A1 (zh) 2013-09-06
MX2007006128A (es) 2007-07-13
US20080014254A1 (en) 2008-01-17
JP2008521757A (ja) 2008-06-26
IL183324A0 (en) 2007-09-20
EP1814843A1 (de) 2007-08-08
HUE027554T2 (en) 2016-10-28
BRPI0518489A2 (pt) 2008-11-25
BR122019018186B8 (pt) 2021-07-27

Similar Documents

Publication Publication Date Title
NO20073286L (no) Stabile krystallmodifikasjoner av DOTAP-klorid
DK1599478T3 (da) Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
DK1888541T3 (da) Benzo(d)isoxazol-3-yl-amin-forbindelser og anvendelse af disse som vanilloidreceptorligander
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
IL177483A0 (en) Means for transdermal administration of nicotine
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
NO20090175L (no) Stabile laquinimod sammensetninger
RS20060320A (en) Substituted indazole-o-glucosides
NO20090295L (no) Substituerte heteroarylderivater
SG130189A1 (en) Substituted indole-o-glucosides
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
DK1730131T3 (da) Glucopyranosyl-substituerede benzol-derivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
UA86042C2 (en) Substituted indazole-o-glucosides
NO20084893L (no) Lyofiliserte terapeutiske peptistoffpreparater
IL189914A0 (en) Substituted 4-phenyltetrahydroisoquinolines, method of producing them, their use as medicament, and also medicament containing them
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
NO20070046L (no) Nytt cykloheksanderivat, prodrug derav og salt derav, og terapeutisk middel inneholdende de samme for diabetes
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
TW200505875A (en) Novel compounds
SE0401762D0 (sv) Novel compounds
TW200639156A (en) New compounds
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse